Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer
Status:
Completed
Trial end date:
2012-02-24
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid
(Zometa®) in the treatment of bone metastases in men with hormone-refractory prostate cancer